Source: Clinical Immunology. Unidades: FMRP, FCFRP
Subjects: COVID-19, ATIVAÇÃO DE COMPLEMENTO
ABNT
SANTOS, Isabel Kinney Ferreira de Miranda e CARDOSO, Cristina Ribeiro de Barros. Commentary on “Complement C3 vs C5 inhibition in severe COVID-19 [Carta]: early clinical findings reveal differential biological efficacy” by D.C. Mastellos et al. Clinical Immunology. Maryland Heights: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. Disponível em: https://doi.org/10.1016/j.clim.2020.108618. Acesso em: 08 nov. 2024. , 2021APA
Santos, I. K. F. de M., & Cardoso, C. R. de B. (2021). Commentary on “Complement C3 vs C5 inhibition in severe COVID-19 [Carta]: early clinical findings reveal differential biological efficacy” by D.C. Mastellos et al. Clinical Immunology. Maryland Heights: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. doi:10.1016/j.clim.2020.108618NLM
Santos IKF de M, Cardoso CR de B. Commentary on “Complement C3 vs C5 inhibition in severe COVID-19 [Carta]: early clinical findings reveal differential biological efficacy” by D.C. Mastellos et al. [Internet]. Clinical Immunology. 2021 ; 222[citado 2024 nov. 08 ] Available from: https://doi.org/10.1016/j.clim.2020.108618Vancouver
Santos IKF de M, Cardoso CR de B. Commentary on “Complement C3 vs C5 inhibition in severe COVID-19 [Carta]: early clinical findings reveal differential biological efficacy” by D.C. Mastellos et al. [Internet]. Clinical Immunology. 2021 ; 222[citado 2024 nov. 08 ] Available from: https://doi.org/10.1016/j.clim.2020.108618